Author Index, Volume 38 (1998)

Achari R, 545
Adedoyin A, 82
Agersø H, 1051
Agrawal MA, 533
Ahlberg AW, 792
Aigner KR, 936
Ajami A, 309
Aldrich TK, 364
Allain H, 256
Allard S, 1042
Altorf B, 1129
Amsden GW, 424
Anandasabapathy S, 101, 295
Anderson GD, 815
Andreadou I, 825
Añonuevo J, 618
Apseloff G, 830
Arancibia A, 533
Arnett DK, 202
Arumugham T, 798
Ashford JW, 236
Awni WM, 642
Axelson JE, 496

Babul N, 74
Baker AB, 160
Bakos L, 554
Bank AK, 202
Barakat H, 1107
Barbhaiya RH, 433, 702
Barditch-Crovo P, 357
Baroldi P, 545
Baruch A, 593
Bauer KS, 337
Bazunga M, 28, 172
Bekersky I, 583
Benet LZ, 1137
Berkovitch M, 926
Bernink PJ, 630
Bernstein KJ, 951
Bhatta S, 765
Biber A, 373
Bieber F, 236
Bleske BE, 708
Blume H, 904
Blumer JL, 122
Blum R, 368
Boeijinga JK, 966
Boike S, 649
Boike SC, 34, 54, 129, 437
Bolton S, 408
Borum J, 593
Borum P, 357
Boswell GW, 583
Bramer SL, 144, 429
Branch RA, 82, 670
Brandon ML, 382
Branebjerg PE, 447
Brayman KL, 268
Briggs WA, 561
Browne DG, 309
Browne TR, 213, 309
Brueckner RP, 227
Buchanan RA, 166
Buell D, 583
BUFUL Study Group, 630
Bugge C, 447
Buier R, 357
Burckart GJ, 981
Burdick J, 561
Burggraaf J, 45
Burke J, 256

Cantore M, 936
Cavanaugh J, 545
Cevallos W, 744
Chan DCF, 912
Chando TJ, 702
Chandrasekaran A, 744
Chan K, 744
Chan P, 1151
Chapelsky MC, 34, 129
Chapman S, 736
Chaudhuri PK, 936
Cheng A, 477
Chen Y, 971
Chen Y-J, 1151
Chiang ST, 467
Chien SC, 90
Ching MI, 151
Choi M, 561
Cho MJ, 807
Chow C-C, 912
Chow MSS, 28, 172, 792
Chung M, 1072
Cleary EW, 685
Clendeninn N, 736
Cleophas TJ, 630
Clerico M, 936
Cockram CS, 912
Cohen A, 545
Cohen AF, 45, 966, 1129
Cohn JN, 202
Colborn D, 1042
Colburn W, 1021, 1122
Colburn WA, 199
Colucci WS, 525
Colussi DM, 727
Cowart DT, 429
Cramer MB, 798
Cressman MD, 670
Croghan IT, 22, 510
Crout RJ, 554
Cummings DM, 1107

Daily JP, 106
Dale LC, 502, 510
Danjou P, 256
DeGraw S, 1096
Delvaux M, 694
de Planque BA, 630
Deraco M, 936
Derendorf H, 373
de Visser SJ, 1129
Dicpinigaitis PV, 364
Dilzer SC, 685
Dimmitt DC, 798
Dixon R, 694
Dobkin JB, 364
Dodo H, 496
Donders SH, 630
Doose DR, 90
Dorr A, 1057
Druce HM, 382
Duan SX, 106
Dube LM, 642

Eastmond R, 819
Ebert U, 720
Ehrenberg BL, 14
Eldon R, 971
Elihu N, 101
Eller MG, 517
Emmert SE, 525
Engelhardt N, 603
Epinette WW, 368
Ermer J, 744
Etheredge R, 34
Etheredge RC, 54
Ette EI, 221, 417
Eustace J, 561
Everett DW, 702

Fairless AJ, 54
Fan C, 172
Farrar HC, 1089
Farrar HC III, 1010
Fasules JW, 402
Ferraro-Borgida MJ, 792
Finkelstein SM, 202
Fiorentini G, 936
Flanigan M, 959
Floc'h R, 807
Fogelman SM, 106
Folan MM, 337
Forbes WP, 144
Ford NF, 246, 347
Forrest A, 151, 649, 1063
Foss JF, 931, 1017
Foulds G, 830
Fransua M, 393
Freedom R, 496
French S, 694
Frishman WH, 2, 101, 295, 393, 477, 765, 887, 1077
Frye RF, 82
Furey SA, 382
Furtek CI, 525

Galant S, 382
Gandon J-M, 256
Gharaibeh MN, 492
Gibaldi M, 898
Giesbrecht E, 496
Gillen LP, 492
Gimenez LF, 561
Glasser SP, 202, 659
Gleiter CH, 680, 904
Goddard JE, 14
Goldberg D, 357
Goldman M, 593
Gow R, 496
Granda BW, 106
Grassi JM, 106
Graves RW, 554
Grebow P, 971
Grebow PE, 276
Greenberg HE, 283
Greenblatt DJ, 14, 106, 112, 572, 603
Greene DS, 433, 702
Griffy K, 1021, 1057, 1122
Groes L, 1051
Groghan IT, 502
Guadagni S, 936
Guilbert E, 1042
Guinta D, 60
Gulanski B, 236
Gumbhir-Shah K, 1096
Gupta SK, 60, 951
Gurell D, 887
Gwilt PR, 945

Haak R, 951
Halstenson C, 798
Hammett JL, 1116
Harder S, 904
Harmatz JS, 14, 106, 112, 603
Harris RZ, 1137
Harsanyi Z, 74
Hartman L, 971
Hassell AE, 593
Heller AH, 715
Heller GV, 792
Heulitt MJ, 402
Higgs C, 736
Hilbert J, 1072
Hillerup S, 447
Himeno H, 442
Hiroto S, 442
Hoerr R, 373
Holz-Slomczyk M, 904
Horton M, 798
Hosmane B, 545
Huang T-Y, 1151
Huang W-P, 1151
Huffman CS, 685
Hulse J, 1021, 1057, 1122
Hurt RD, 22, 502, 510
Hwang S, 60

Igarashi T, 1025
Ilson B, 129, 649
Ilson BE, 34, 437
Imbimbo BP, 610
Ito MK, 331
Ito S, 496
Izzo JL Jr, 151

Jackson DL, 554
Jackson EK, 670
James LP, 1089
Jara H, 918
Jiang N-S, 502, 510
Jochemsen R, 315
Jorkasky DK, 34, 54, 129, 413, 437, 649
Jovanovic L, 636

Jung D, 1021, 1057, 1122
Jusko WJ, 1096, 1116

Kaiser L, 715
Kalayjian RC, 357
Kaminskis A, 227
Kanamaru M, 40
Kaplan GB, 14
Kashuba ADM, 424
Kates RE, 1057
Kato K, 1025
Kato T, 1025
Kazierad DJ, 618, 649
Kearns GL, 122, 402, 424, 994, 1010, 1089
Keefe DL, 1, 569
Kellerman DJ, 1096
Kemp J, 694
Kertland H, 28
Keung ACF, 517
Kihara M, 442
Kinameri K, 1025
King SP, 276
Kirch W, 720
Kisicki J, 429
Klein J, 926
Klotz U, 904
Kluger J, 172
Knowles SR, 1003
Knowlton PW, 178
Kochak GM, 166
Koch P, 1096
Ko GTC, 912
Koneru B, 429
Korecka M, 268
Koren G, 496, 926
Koshiba Y, 1025
Kost CK Jr, 670
Kostopanagiotou G, 825
Kotegawa T, 68
Kottis G, 825
Koup JR, 178, 815
Kovacs SJ, 413
Kraft W, 283
Kramer WG, 708
Kroboth PD, 337
Kroon JM, 1129
Kruse T, 1051
Kuhlmann J, 904
Kurita Y, 1025
Ku Y-M, 959

Laberge F, 74
LaBoy-Goral L, 830
Lachaud-Pettiti V, 315
Lam CWK, 912
Langenbacher K, 246
Langenbacher KM, 347
Lasagna L, 570, 575
Lasseter KC, 227, 347, 685
Laufen H, 138
Laughton W, 971
Laughton WB, 276
Laveille C, 315
Lawrence V, 1072
Lawson GM, 502, 510
Lazarus SC, 577
Leaf CD, 945
LeBel M, 1042
Lechin AE, 918
Lechin F, 918
Lechin ME, 918
Leclerc V, 694
Le Coz F, 256
Lederman M, 357
Lee J-I, 981
Lee P, 593
Lefèvre GY, 727
Lehmann DF, 463, 783
Lester RS, 926
Lettieri J, 236, 715
Lettis S, 819
Letzig L, 994
Letzig LG, 1010
Levitsky J, 887
Levy R, 807
Lewis DA, 22
Lietman P, 357
Lilley SH, 1107
Lin E, 227
Linnen P, 545
Liu BA, 1003
Liu Y-C, 1151
Li X-Y, 945
Lockhart EA, 382
Loi C-M, 178, 815
Lo M-W, 525
Lücker PW, 533
Ludden TM, 221, 417
Lu H, 525
Lu W, 625
Luzier AB, 618
Lyness WH, 184

Mahmood I, 324
Maish WA, 1010
Mak TWL, 912
Mantha S, 433
Mant T, 610
Marino MR, 246, 347
Marino MT, 227
Markesbery WR, 236
Markland C, 971
Marotti T, 1089
Marrero I, 1155
Marshall JD, 994
Martin DE, 34, 129, 413, 437, 649
Maruyama I, 540
Mas J, 236
Massarella J, 28
Masson E, 1042
Masuhara K, 1025
Mathew S, 561
Matsukubo S, 68
Matzke GR, 82
Mauro K, 82
Mayersohn M, 467
Mazzu A, 715
McCormick GC, 276
McCubbin MM, 1010
McGill CC, 792
McVeigh GE, 202
Medicis J, 783
Mehlisch DR, 455
Meikle AW, 54
Meinders AJ, 1129
Meineke I, 680
Merz M, 1144
Mick R, 268
Miller VM, 22
Minamisawa K, 442
Min DI, 959
Miura T, 654
Mizutani M, 654
Monaghan J, 736
Montgomery PA, 184
Moore LW, 807
Moore PA, 554
Moran HB, 807
Morgan DJ, 202
Morse PD, 463
Moss J, 931, 1017
Moulin D, 74
Moyle GJ, 736
Moyna NM, 792
Mroczkowski PJ, 1137
Mullican W, 715
Mure P, 382

Nafziger AN, 424
Nagai H, 1025
Nagai N, 1025
Nagamochi I, 442
Nakamura K, 68
Nakano S, 68
Nakashima M, 40, 540
Nakatsuka K, 68
Nanhekhan LV, 1129
Narang PK, 1042
Narang-Sachdeo S, 184
Naruse M, 442
Nattestad A, 447
Nawarskas JJ, 618
Nayak RK, 90
Nelson MR, 736
Neuman E, 315
Newman N, 463
Nicklas JM, 708
Nielsen H, 447
Niemeyer MG, 630
Nix DE, 1063
Noe D, 357
Noorduin H, 951
Noorisa M, 429
Nowak I, 268
Nulman I, 926

O'Connor M, 931, 1017
O'Dea RF, 642
Oertel R, 720
Offord KP, 22, 502, 510
Ogata H, 1025
Ohno T, 1025
Olson NZ, 1155
Olson SC, 753
Orazem J, 236
Orozco B, 918
Osborne B, 492
Osman M, 744
Otvos J, 1107

Padgett CS, 166
Page JG, 166
Pak CYC, 1035
Palumbo G, 936
Papadimitriou L, 825
Paquet F, 1042
Parisot CY, 727
Park J-S, 433
Pastuszak A, 926
Patat A, 256
Paulos C, 533
Paulus H, 904
Perhach JL, 184
Pesco-Koplowitz L, 593
Peters R, 166
Pettigrew LC, 236
Phillips K, 1072
Pieters MSM, 1129
Poethko-Müller C, 904
Poindexter J, 1035
Pollack GM, 807
Post JB IV, 2
Pouletty P, 807
Pouriezis T, 825
Pozone T, 936
Prenner BM, 382
Prince W, 736
Provencher L, 74

Rada I, 918
Radick LE, 945
Ramey KL, 413
Ramzan I, 160
Randinitis EJ, 178
Raschke R, 1057
Rauf K, 364
Rautureau J, 694
Raymond RH, 347
Reed MD, 122
Regaglia F, 160
Ritschel WA, 533
Ritter MA, 525
Ritzau M, 447
Roizen MF, 931, 1017
Rosenberg A, 184
Rosenberg HC, 496
Rowe WB, 357
Rucinska E, 525
Rud KS, 22
Rudolph R, 467
Ruml LA, 1035
Ruzicka BB, 236

Sachdeo RC, 184
Sathyan G, 951
Sawyer CA, 160
Scatina J, 744
Scavone JM, 603
Schade DS, 636
Scharpf F, 138
Scheel PJ Jr, 561
Schentag JJ, 1063
Schmider J, 112
Schmitt FA, 236
Schneider J, 636
Schneider LG, 554
Schoemaker RC, 45, 1129
Schook CE, 966
Schou S, 447
Schroeder DR, 502, 510

Schroeder TJ, 807
Schuster BG, 227
Schwartzel E, 368
Schwartz JI, 492
Sedman AJ, 178
Seiberling M, 1144
Sellers M, 694
Shader RI, 14, 106, 112, 603
Shah AK, 798
Shah J, 60
Sharma A, 1116
Shaw LM, 268
Shear N, 926
Shear NH, 1003
Shibakawa M, 654
Shindo K, 442
Shionoiri H, 442
Shumaker RC, 184
Shyu WC, 433, 702
Siepmann M, 720
Simcoe D, 971
Sinha S, 1077
Sisenwine SF, 744
Siskin S, 368
Skoglund LA, 447
Skowron G, 357
Slugg PH, 1116
Smith CD, 236
Smith DA, 685
Smithers JA, 753
Smyrniotis V, 825
Someya K, 1025
Sourgens H, 373
Spivey JM, 1107
Stanislaus F, 904
Steinbrede H, 373
Stern R, 178
Stern RH, 753
Stowe CD, 1089
Strenkoski-Nix LC, 1063
Sugimoto K, 442
Sugiura Y, 654
Sung BH, 151
Sun H, 221, 417
Sunshine A, 1155
Suri A, 144
Sweeney JA, 337
Szabo GK, 309

Takahashi H, 1025
Takano Y, 654
Takasaki I, 442
Takatsu F, 654
Tanaka K, 654
Tanaka Y, 1025
Tarnowski TL, 1057
Taylor BJ, 402, 1089
Tenero D, 129
Tenero DM, 34
Terpstra IJ, 45
Theodoraki K, 825
Thoden WR, 382
Thomann P, 1144
Thompson PD, 792
Thomsen MS, 1051
Tikhtman AJ, 236
Tirado S, 1155
Tofovic SP, 670
Toh J, 525
Tonn GR, 496
Tran C, 1003
Tran HT, 28
Trépanier EF, 424
Trocherie S, 256
Troetel WM, 610
Troy S, 256
Troy SM, 467
Tsang LWW, 912
Tsujino D, 1025
Tsunoda SM, 1137
Tsuruta K, 40, 540
Tsutsumi K, 68
Tullock W, 337

Uchida E, 1129
Uchida N, 1129
Uderman HD, 246
Ueda S, 442
Uematsu T, 540
Ueno K, 654
Umemura K, 40, 540
Uretsky BF, 525

Vachharajani NN, 433, 702
Vadlamudi S, 1107
Vahdat S, 765
Vallée F, 1042
van den Anker JN, 122
van den Ende R, 966
van der Dijs B, 918
van der Heijden M, 630
van der Meulen J, 630
van der Wall EE, 630
van Gerven JMA, 1129
van Meegen E, 966
Van Peer A, 951
Vashi V, 1072
Vassos AB, 178
Venkatakrishnan K, 112
Verjee Z, 496
Vincent J, 830
von Moltke LL, 106, 112

Wada Y, 1025
Waldman SA, 283, 492
Walker SA, 90
Wang L, 971
Watkins S, 685
Weinstein S, 382
Weir SJ, 517, 798
Wei S, 625
Wekstein DR, 236
Welage LS, 708
Wells TG, 402, 994
Wermeling DP, 236
Wesnes KA, 720
Wetzelsberger KM, 533
Whalen JJ, 945
Wheat LJ, 593
White CM, 172, 792
Willavize S, 830
Williams RR, 90
Wilson DE, 54
Wilson MF, 151, 618
Woestenborghs R, 593
Wong R, 1021, 1122
Wong SL, 642
Wong YN, 276, 971
Woods JH, 773
Wright CE, 337
Wuermser L-A, 1035
Wu J, 593

Xia Q, 625
Xie T, 382

Yashar PR, 393
Yasuda G, 442
Yasuda K, 1129
Yasuhara H, 1129
Yatsuka YI, 68
Yeates R, 138
Yeung VTF, 912
Yokoyama A, 1025
Youle M, 736
Young MA, 819
Yuan C-S, 931, 1017

Zalzstein E, 496
Zariffa N, 129, 649
Zhang Q, 625
Zhou D, 625
Zhou H, 593
Ziering R, 382
Zimmermann T, 138

Subject Index, Volume 38 (1998)

An "A" preceding a page number indicates an abstract.

ABT-761
effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers, 642
Acarbose
impairment of absorption of digoxin by acarbose, 654
Acetaminophen
coadministration of acetaminophen and troglitazone: pharmacokinetics and safety, 818
Acetazolamide
pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude, 533
Acipimox
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
Adverse Effects
gender differences in adverse drug reactions, 1003
paradoxical hypotension and bradycardia after intravenous arginine vasopressin, 283
Age. *See also* **Geriatrics; Pediatrics**
influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers, 715
Albuterol
pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers, 1096
Alprazolam
do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?, 337
single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects, 14
Alzheimer's disease
application of population pharmacokinetics to the phase II development of an anti- Alzheimer's disease compound, S12024, 315
pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease, 236
Amitriptyline
multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations, 60
Amphotericin B
AmBisome (liposomal amphotericin B): a comparative review, 583

Analgesia
analgesic dose-response relationship of ibuprofen 50, 100, 200, and 400 mg after surgical removal of third molars: a single-dose, randomized, placebo-controlled, and double-blind study of 304 patients, 447
analgesic efficacy and safety of (R)-ketoprofen in postoperative dental pain, 11S
comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain, 74
double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery, 455
onset and duration of analgesia for low-dose ketoprofen in the treatment of postoperative dental pain, 1155
tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction, 554
Aneurysms
matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target, 1077
Angiotensin-Converting Enzyme Inhibitors
use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium-channel blockers, 477
Arginine Vasopressin
paradoxical hypotension and bradycardia after intravenous arginine vasopressin, 283
ART-123
novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers, 540
pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers, 40
Aspirin
tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction, 554
Asthma
inflammation, inflammatory mediators, and mediator antagonists in asthma, 577
Atorvastatin
atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine, 753
Azithromycin
comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers, 830

Baclofen
inhibition of capsaicin-induced cough by the gamma-aminobutyric acid agonist baclofen, 364
Benzodiazepines
problems and opportunities in regulation of benzodiazepines, 773
Bezold-Jarisch Reflex
efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Bezold-Jarisch reflex, 172
BMS-188494
clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers, 1116
Bromfenac
double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery, 455
metabolic disposition of 14C-bromfenac in healthy male volunteers, 744
Brompheniramine
brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial, 382
Bumetanide
pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients, 994
randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the Bumetanide and Furosemide on Lipid Profile (BUFUL) clinical study report, 630

Calcipotriene
evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study, 368
Calcium
sodium-calcium ion membrane exchanger: physiologic significance and pharmacologic implications, 393
Calcium-Channel Blockers
relevance of T-type calcium antagonists: a profile of mibefradil, 659
use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium-channel blockers, 477
Cancer
comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain, 74
pharmacokinetics of mitomycin C in pelvic stop-flow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer, 936
population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program, 1025
Cardiovascular System
chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane, 101
droperidol elimination after cardiopulmonary bypass surgery, 160
efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Bezold-Jarisch reflex, 172
importance of arterial compliance ion cardiovascular drug therapy, 202
innovative drug treatments for viral and autoimmune myocarditis, 295
innovative pharmacologic approaches to cardiopulmonary resuscitation, 765
intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response, 496
paradoxical hypotension and bradycardia after intravenous arginine vasopressin, 283
pharmacokinetics of intravenous and oral losartan in patients with heart failure, 525
pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease, 792
pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure, 708
regulating angiogenesis: a new therapeutic strategy, 898
sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury, 887
vasoreactivity in pre- and postmenopausal women: evaluation by pharmacodynamic modeling, 151
Cerivastatin
influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers, 715
Chlorzoxazone
use of chlorzoxazone as an *in vivo* probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure, 82
Cilostazol
pharmacokinetics of multiple-dose cilostazol in middle-age and elderly men and women, 144
Cimetidine
effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus, 463
influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine, 467
Ciprofloxacin
pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers, 1063
Cisplatin
population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program, 1025
Clarithromycin
comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers, 830
Clinical Pharmacology
Evening Reflections, 575
maturation of clinical pharmacology: recognizing the contributions of Dr. Louis Lasagna, 572
presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 570
regulating angiogenesis: a new therapeutic strategy, 898
teaching clinical pharmacology and therapeutics: selective for fourth-year medical students, 670
Clinical Trials
brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial, 382
comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain, 74
cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril, 442
independence and statistical inference in clinical trial designs: a tutorial review, 408
laboratory values and vital signs in male smokers and non-smokers in phase I trails: a retrospective comparison, 1144
phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers, 45
placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful, 636
randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension, 1151
randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the Bumetanide and Furosemide on Lipid Profile (BUFUL) clinical study report, 630
R-Ketoprofen in Clinical Trials, 1S
serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled study, 918
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?, 413
Codeine
tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction, 554
Coumarins
lack of interaction between tramadol and coumarins, 966
Cyclosporine
comparison of two cyclosporine formulations in

healthy volunteers: bioequivalence of the new Sang-35 formulation and Neorol, 807
effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?, 959
levofloxacin does not alter cyclosporine disposition, 90
CYP1A2
absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase, 424
Cysteine
pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteine prodrug, and cysteine, 945
Cystic Fibrosis
pharmacokinetics of famotidine in patients with cystic fibrosis, 1017
Cytochrome P450
preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women, 1137
protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir, 106
use of chlorzoxazone as an *in vivo* probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure, 82

Deferoxamine
chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane, 101
Dementia
KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers, 373
Demographics
pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers, 1129
Dental Pain
analgesic dose-response relationship of ibuprofen 50, 100, 200, and 400 mg after surgical removal of third molars: a single-dose, randomized, placebo-controlled, and double-blind study of 304 patients, 447
analgesic efficacy and safety of (R)-ketoprofen in postoperative dental pain, 1S
double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery, 455
onset and duration of analgesia for low-dose ketoprofen in the treatment of postoperative dental pain, 1155
tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction, 554
Dexrazoxane
chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane, 101
Dextroamphetamine
comparison of single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers, 971
Diabetes Mellitus
lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemia obese women with controlled type 2 diabetes mellitus, 1107
placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful, 636
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
Didanosine
effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus-positive patients, 1057
Digoxin
effect of troglitazone on steady-state pharmacokinetics of digoxin, 178
impairment of absorption of digoxin by acarbose, 654
Diphenhydramine
pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers, 603
Dislipidemia
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
Diuretics
use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium-channel blockers, 477
Dolasetron Mesylate
pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment, 798
Doxazosin
pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin, 1072
Droperidol
droperidol elimination after cardiopulmonary bypass surgery, 160
Drug Delivery
fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current, 951
Drug Development
application of population pharmacokinetics to the phase II development of an anti- Alzheimer's disease compound, S12024, 315
performance of human mass balance studies with stable isotope-labeled drug and continuous flow-isotope ratio mass spectrometry: a progress report, 309
stable isotope techniques in early drug development: an economic evaluation, 213
Drug Interactions
ABT-761 and ethinyl estradiol, 642
ABT-761 and levonorgestrel, 642
acarbose and digoxin, 654
acetaminophen and troglitazone, 819
atorvastatin and terfenadine, 753
azithromycin and rifabutin, 830
cimetidine and sulfamethoxazole, 463
cimetidine and venlafaxine, 467
ciprofloxacin and piperacillin and piperacillin/tazobactam, 1063
clarithromycin and rifabutin, 830
coumarins and tramadol, 966
cyclosporine and levofloxacin, 90
dextroamphetamine and modafinil, 971
didanosine and ganciclovir, 1051
digoxin and acarbose, 654
digoxin and troglitazone, 178
doxazosin and finasteride, 1072
effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?, 959
eprosartan and warfarin, 649
erythromycin and felbamate, 184
erythromycin and tiagabine, 1051
ethinyl estradiol and ABT-761, 642
ethinyl estradiol and rifabutin and rifampicin, 1042
felbamate and erythromycin, 184
finasteride and doxazosin, 1072
finasteride and terazosin, 1072
ganciclovir and didanosine, 1051
levofloxacin and cyclosporine, 90
levonorgestrel and ABT-761, 642
modafinil and dextroamphetamine, 971
norethindrone and rifabutin and rifampicin, 1042
ondansetron and thiopental, 825
pentoxifylline potentiates *in vitro* lymphocyte suppression by glucocorticoids and immunosuppressive drugs, 561
piperacillin and ciprofloxacin and piperacillin/tazobactam, 1063
piperacillin/tazobactam and piperacillin and ciprofloxacin, 1063
rifabutin and azithromycin, 830
rifabutin and clarithromycin, 830
rifabutin and rifampicin and ethinyl estradiol, 1042
rifabutin and rifampicin and norethindrone, 1042
rifampicin and rifabutin and ethinyl estradiol, 1042
rifampicin and rifabutin and norethindrone, 1042
single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers, 276
sulfamethoxazole and cimetidine, 463
terazosin and finasteride, 1072
terfenadine and atorvastatin, 753
thiopental and ondansetron, 825
tiagabine and erythromycin, 1051
tramadol and coumarins, 966
troglitazone and acetaminophen, 819
troglitazone and digoxin, 178
venlafaxine and cimetidine, 467
warfarin and eprosartan, 649
Drug Metabolism
absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase, 424
effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin, 331
metabolic disposition of 14C-bromfenac in healthy male volunteers, 744
preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women, 1137
protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir, 106
use of chlorzoxazone as an *in vivo* probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure, 82

Editorials
Editor's Note, 569
A New Look, 1
Products Approved for Marketing During 1997, 199
R-Ketoprofen in Clinical Trials, 1S
Elderly Patients. *See* **Geriatrics**
Eprosartan
dose proportionality study of eprosartan in healthy male volunteers, 34
effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension, 437
eprosartan does not affect the pharmacodynamics of warfarin, 649
pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment, 129
Eptastigmine
maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers, 610
Erythromycin
effect of multiple doses of rifampin on the (14C *N*-methyl) erythromycin breath test in healthy male volunteers, 492
evaluation of the potential interaction between

felbamate and erythromycin in patients with epilepsy, 184
lack of pharmacokinetic interaction between tiagabine and erythromycin, 1051
Ethinyl estradiol
effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers, 642
effects of rifabutin and rifampicin on the pharmacokinetics of ethinyl estradiol and norethindrone, 1042
Ethnicity
pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers, 1129
Ethylenediaminetetraacetic acid
chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane, 101
Extracorporeal Membrane Oxygenation
pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation, 402

Famotidine
effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone, 429
pharmacokinetics of famotidine in patients with cystic fibrosis, 1017
Felbamate
evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy, 184
Fenoldopam
fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies, 2
Fentanyl
fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current, 951
Finasteride
pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin, 1072
Fluconazole
accumulation of fluconazole in scalp hair, 138
Flurbiprofen
clinical endoscopic evaluation of gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol: a randomized, single-blind, placebo-controlled trial, 19S
Furosemide
randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the Bumetanide and Furosemide on Lipid Profile (BUFUL) clinical study report, 630

Ganciclovir
absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus-positive patients, 1122
effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus-positive patients, 1057
steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus, 1021
Gastrointestinal System
effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin, 331
effects of low-dose morphine on gastric emptying in healthy volunteers, 1017
gut motility and transit changes in patients receiving long-term methadone maintenance, 931
Gender
effects of gender on adrenergic receptor responsiveness, 618
gender differences in adverse drug reactions, 1003
Geriatrics
maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers, 610
pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers, 603
pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease, 792
pharmacokinetics of multiple-dose cilostazol in middle-age and elderly men and women, 144
randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension, 1151
single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects, 14
Glimepiride
placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful, 636
Glucocorticoids
pentoxifylline potentiates *in vitro* lymphocyte suppression by glucocorticoids and immunosuppressive drugs, 561
Granisetron
efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Bezold-Jarisch reflex, 172
Grapefruit Juice
effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?, 959

Hemodynamics
short-term effects of nicardipine and propranolol on ocular and systemic hemodynamics in healthy Japanese subjects, 68
Hepatic Function
effect of hepatic impairment on the pharmacokinetics of zolmitriptan, 694
pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis, 347
pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction, 517
High Altitude
pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude, 533
Hormone Replacement Therapy
lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemia obese women with controlled type 2 diabetes mellitus, 1107
Human Immunodeficiency Virus
absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus-positive patients, 1122
effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus, 463
effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus-positive patients, 1057
pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection, 593
phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus, 357
steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus, 1021
Hydrogen
sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury, 887
Hypertension
effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension, 437
fenoldopam: a new dopamine agonist for the treatment of hypertensive urgencies and emergencies, 2
pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study, 685
randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension, 1151
Hypokalemia
effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss, 1035
Hypotension
efficacy of intravenous granisetron in suppressing the bradycardia and hypotension associated with a rabbit model of the Bezold-Jarisch reflex, 172
paradoxical hypotension and bradycardia after intravenous arginine vasopressin, 283

Ibuprofen
analgesic dose-response relationship of ibuprofen 50, 100, 200, and 400 mg after surgical removal of third molars: a single-dose, randomized, placebo-controlled, and double-blind study of 304 patients, 447
Imidapril
cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril, 442
Immunosuppressive Drugs
pentoxifylline potentiates *in vitro* lymphocyte suppression by glucocorticoids and immunosuppressive drugs, 561
Inflammation
inflammation, inflammatory mediators, and mediator antagonists in asthma, 577
Irbesartan
lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers, 433
oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers, 702
pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects, 246
pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis irbesartan, 347
Itraconazole
pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection, 593

KA 672-HCl
KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers, 373

Ketoprofen
analgesic efficacy and safety of (R)-ketoprofen in postoperative dental pain, 11S
onset and duration of analgesia for low-dose ketoprofen in the treatment of postoperative dental pain, 1155
R-Ketoprofen in Clinical Trials, 1S
stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers, 3S
Ketorolac
preclinical enantioselective pharmacology of (R)- and (S)-ketorolac, 24S

Letrozole
plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor, 727
Levofloxacin
levofloxacin does not alter cyclosporine disposition, 90
Levonorgestrel
effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers, 642
Loratadine
brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial, 382
Losartan
pharmacokinetics of intravenous and oral losartan in patients with heart failure, 525
Lovastatin
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
Lymphocytes
pentoxifylline potentiates *in vitro* lymphocyte suppression by glucocorticoids and immunosuppressive drugs, 561

Magnesium
effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss, 1035
Metalloproteinases
matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target, 1077
Methadone
gut motility and transit changes in patients receiving long-term methadone maintenance, 931
Methylphenidate
single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers, 276
Metoclopramide
pharmacokinetics of metoclopramide in neonates, 122
Metrifonate
pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease, 236
Mibefradil
relevance of T-type calcium antagonists: a profile of mibefradil, 659
Mitomycin C
pharmacokinetics of mitomycin C in pelvic stop-flow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer, 936
Modafinil
comparison of single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers, 971
single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers, 276
Morphine
comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain, 74
effects of low-dose morphine on gastric emptying in healthy volunteers, 1017
Mycophenolic acid
pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function, 276

Naproxen
single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers, 625
NAT-2
absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase, 424
Nicardipine
short-term effects of nicardipine and propranolol on ocular and systemic hemodynamics in healthy Japanese subjects, 68
Nicotine. *See also* **Smoking**
application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy, 502
application of urine nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy, 510
plasma nitric oxide before and after smoking cessation with nicotine nasal spray, 22
Nitrazepam
pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers, 1129
Nitric Oxide
plasma nitric oxide before and after smoking cessation with nicotine nasal spray, 22
Norethindrone
effects of rifabutin and rifampicin on the pharmacokinetics of ethinyl estradiol and norethindrone, 1042
Nuclear Factor KappaB
nuclear factor kappaB: important transcription factor and therapeutic target, 981

Obesity
lipid and lipoprotein responses to oral combined hormone replacement therapy in normolipemia obese women with controlled type 2 diabetes mellitus, 1107
Ondansetron
influence of ondansetron on thiopental hypnotic requirements, 825
OROS
multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations, 60
2-Oxothiazolidine-4-Carboxylate
pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteine prodrug, and cysteine, 945
phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus, 357

Paracetamol
clinical endoscopic evaluation of gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol; a randomized, single-blind, placebo-controlled trial, 19S
Pediatrics
intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response, 496
pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients, 994
pharmacokinetics and pharmacodynamics of famotidine in infants, 1089
pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation, 402
pharmacokinetics of metoclopramide in neonates, 122
serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled study, 918
steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety, 926
Pentoxifylline
pentoxifylline potentiates *in vitro* lymphocyte suppression by glucocorticoids and immunosuppressive drugs, 561
Pharmacodynamics
albuterol, 1096
alprazolam, 14
amitriptyline, 60
baclofen, 364
BMS-188494, 1116
bumetanide, 994
cisplatin, 1025
diphenhydramine, 603
effects of gender on adrenergic receptor responsiveness, 618
eptastigmine, 610
famotidine, 1089
hormone replacement therapy, 1107
irbesartan, 246, 347
metrifonate, 236
morphine, 1017
nicardipine, 68
nicotine, 502, 510
nitrazepam, 1129
L-2-oxothiazolidine-4-carboxylic acid, 357
pravastatin, 331
propranolol, 68
pyridostigmine bromide, 227
ranitidine, 402
terazosin, 545
vasoreactivity in pre- and postmenopausal women: evaluation by pharmacodynamic modeling, 151
venlafaxine, 256
Pharmacoeconomics
pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services, 783
Pharmacoepidemiology
gender differences in adverse drug reactions, 1003
Pharmacokinetics
acetazolamide, 533
albuterol, 1096
alprazolam, 14
amitriptyline, 60
ART-123, 40, 540
assessment of drug accumulation in the evaluation of pharmacokinetic data, 685
balanced designs in longitudinal population pharmacokinetic studies, 417
BMS-188494, 1116
bumetanide, 994
cerivastatin, 715
cilostazol, 144
cisplatin, 1025
coadministration of acetaminophen and troglitazone: pharmacokinetics and safety, 818
cyclosporine, 807
cysteine, 945
development of a limited sampling approach in pharmacokinetic studies: experience with the antiepilepsy drug tiagabine, 324
dextroamphetamine, 971
diphenhydramine, 603
dolasetron mesylate, 798
dose proportionality study of eprosartan in healthy male volunteers, 34

droperidol, 160
effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter?, 959
effect of multiple doses of rifampin on the (14C *N*-methyl) erythromycin breath test in healthy male volunteers, 492
eprosartan, 129
erythromycin, 1051
ethinyl estradiol, 1042
famotidine, 1089, 429, 1010
fluconazole, 138
ganciclovir, 1021, 1122
ignorability and parameter estimation in longitudinal pharmacokinetic studies, 221
irbesartan, 246, 347, 433, 702
isotretinoin, 926
itroconazole, 593
KA 672-HCl, 373
ketoprofen, 3S
letrozole, 727
losartan, 517
methadone, 931
methylphenidate, 276
metoclopramide, 122
metrifonate, 236
mitomycin C, 936
modafinil, 276, 971
mycophenolic acid, 268
naproxen, 625
nelfinavir, 736
nicotine nasal spray, 22
nitrazepam, 1129
norethindrone, 1042
2-oxothiazolidine-4-carboxylate, 945
L-2-oxothiazolidine-4-carboxylic acid, 357
potassium-magnesium citrate, 1035
propafenone, 496
pyridostigmine bromide, 227
ranitidine, 402
rifampin, 492
rifapentine, 517
S12024, 315
scopolamine, 721
testosterone, 54, 792
tiagabine, 324, 1051
torsemide, 708
troglitazone, 815
venlafaxine, 256, 467
vesnarinone, 429
when are bioavailability studies required? A German proposal, 904
YM934, 45
zalcitabine, 28
zolmitriptan, 685, 694
zonisamide, 166

Piperacillin
pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers, 1063

Piperacillin/Tazobactam
pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers, 1063

Potassium-Magnesium Citrate
effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss, 1035

Pravastatin
effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin, 331

Progestins
preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women, 1137

Propafenone
intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response, 496

Propranolol
short-term effects of nicardipine and propranolol on ocular and systemic hemodynamics in healthy Japanese subjects, 68

Protein C Pathway
novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers, 540

Psoriasis
evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study, 368

Psychopharmacology
do alprazolam-induced changes in saccadic eye movement and psychomotor function follow the same time course?, 337

Pyridostigmine Bromide
population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans, 227

Ranitidine
pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation, 402

Renal Function
effects of renal impairment in the pharmacokinetics of zalcitabine, 28
pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment, 129
pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function, 276
pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment, 798

Rhinitis
brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial, 382

Rifabutin
comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers, 830
effects of rifabutin and rifampicin on the pharmacokinetics of ethinyl estradiol and norethindrone, 1042

Rifampicin
effects of rifabutin and rifampicin on the pharmacokinetics of ethinyl estradiol and norethindrone, 1042

Rifapentine
pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction, 517

Ritonavir
protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir, 106

S12024
application of population pharmacokinetics to the phase II development of an anti- Alzheimer's disease compound, S12024, 315

Safety
analgesic efficacy and safety of (R)-ketoprofen in postoperative dental pain, 11S
coadministration of acetaminophen and troglitazone: pharmacokinetics and safety, 818
comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain, 74
evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study, 368
influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers, 715
KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers, 373
pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers, 1096
pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease, 236
pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers, 40
phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers, 45
randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension, 1151

Scopolamine
pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration, 720

Seizures
steady-state pharmacokinetics of zonisamide, and antiepileptic agent for treatment of refractory complex partial seizures, 166

Serotonin
serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a double-blind, crossover, placebo-controlled study, 918

Smoking. *See also Nicotine*
laboratory values and vital signs in male smokers and non-smokers in phase I trails: a retrospective comparison, 1144

Sodium
sodium-calcium ion membrane exchanger: physiologic significance and pharmacologic implications, 393
sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury, 887

Sulfamethoxazole
effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus, 463

Terazosin
pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin, 1072

Terbinafine
absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase, 424

Terfenadine
atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine, 753

Testosterone
bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men, 54
pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease, 792

Thiazides
effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss, 1035

Thiopental
influence of ondansetron on thiopental hypnotic requirements, 825

Tiagabine
development of a limited sampling approach in pharmacokinetic studies: experience with the antiepilepsy drug tiagabine, 324
lack of pharmacokinetic interaction between tiagabine and erythromycin, 1051

Tianeptine
serotonin uptake-enhancing drug tianeptine suppresses asthmatic symptoms in children: a

double-blind, crossover, placebo-controlled study, 918
Tolerability
influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers, 715
KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers, 373
phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers, 45
short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dislipidemia, 912
Tolerance
clinical endoscopic evaluation of gastroduodenal tolerance to (R)-ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol; a randomized, single-blind, placebo-controlled trial, 19S
Torsemide
pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure, 708
Tramadol
double-blind, single-dose comparison of bromfenac sodium, tramadol, and placebo after oral surgery, 455
lack of interaction between tramadol and coumarins, 966
Tramadol Hydrochloride
tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction, 554
Troglitazone
effect of troglitazone on steady-state pharmacokinetics of digoxin, 178
effect of troglitazone on urinary excretion of 6β-hydroxycortisol, 815

Uric Acid
effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension, 437

Venlafaxine
absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects, 256
influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine, 467
Vesnarinone
effect of increasing gastric pH with famotidine on the absorption and oral pharmacokinetics of the inotropic agent vesnarinone, 429
Vitamin B Complex
randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension, 1151

Warfarin
eprosartan does not affect the pharmacodynamics of warfarin, 649

Xanthine Oxidase
absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase, 424

YM934
phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers, 45
Young Adults
pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers, 603
single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects, 14

Zalcitabine
effects of renal impairment in the pharmacokinetics of zalcitabine, 28
Zolmitriptan
effect of hepatic impairment on the pharmacokinetics of zolmitriptan, 694
pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study, 685
Zonisamide
steady-state pharmacokinetics of zonisamide, and antiepileptic agent for treatment of refractory complex partial seizures, 166